Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03908164
Other study ID # 2018.0297
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date May 7, 2019
Est. completion date May 2021

Study information

Verified date November 2020
Source St George's, University of London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multicentre study to evaluate the impact of timing of whooping cough (pertussis) vaccination in pregnancy, with participants randomised to receive whooping cough vaccination at one of three time points in pregnancy.


Description:

Pertussis is a highly infectious respiratory illness caused by Bordetella pertussis, which characteristically causes paroxysms of coughing with an associated inspiratory 'whoop'. In young infants the clinical presentation can be atypical, is frequently associated with apnoeic episodes and can cause significant morbidity and mortality. Following the introduction of pertussis vaccination into routine infant schedules worldwide there was a significant reduction in the incidence of pertussis. However, recently in a number of countries, despite high vaccine coverage, there has been a resurgence of pertussis disease associated with an increase in infant deaths. Various strategies to control the increasing burden of infant pertussis disease have been considered including cocooning, a strategy in which close contacts of an infant are vaccinated, a neonatal dose of a pertussis containing vaccine, the addition of an adolescent dose to the schedule and vaccination in pregnancy. Of these, the latter has gained most support. Vaccination in pregnancy is a strategy which relies on effective transport of antibody across the placenta, a process which depends on the antibody available, the gestation of the pregnancy and the health of the placenta. In the case of pertussis, the main aim is to prevent disease in babies (prior to the age of routine vaccination) as they have a higher mortality than any other age group from pertussis disease. It is now clear that pertussis vaccination in pregnancy can reduce the burden of disease in young infants in the period prior to them being fully immunised, and can do so safely. However, it is not established whether there is an optimal time to vaccinate in pregnancy to ensure maximal protection of the infant. This is reflected in the different guidelines currently in place in different countries: in the UK vaccination is advised from 16 weeks gestation, in Canada from 26 weeks, in the USA from 27 weeks and in Australia from 28 weeks. While some studies have suggested that vaccination later in pregnancy can achieve higher antibody concentrations in the newborn, others have found earlier vaccination provides improved immunity compared to later vaccination. The significance of this is that if earlier vaccination is shown to be equivalent, there are clear logistical benefits in allowing the widest possible time window in order to maximise the opportunities for pregnant women to be vaccinated and thereby improve vaccine coverage. When the pertussis vaccination in pregnancy programmes were first implemented, vaccination was recommended in the third trimester (USA 27-36 weeks, UK 28-32 weeks). This decision was based on the hypothesis that vaccination would be most effective if it was timed to allow the peak in maternal antibody levels after vaccination to coincide with the time of most efficient placental transport. There is a significant lack of agreement on optimal timing of pertussis vaccination in pregnancy due to conflicting data. This is the rationale for this randomised controlled trial. In this study all participants will receive a pertussis containing vaccine licensed for use in pregnancy. In the UK currently the vaccine used is Boostrix-IPVĀ® manufactured by GlaxoSmithKline. This vaccine contains pertussis toxin (PT) (8 micrograms), filamentous haemagglutinin (FHA) (8 micrograms) and pertactin (PRN) (2.5 micrograms) as well as diphtheria toxoid (not less than 2 international units), tetanus toxoids (not less than 20 international units) and inactivated polio virus types 1-3 (type 1 40 D-antigen unit, type 2 8 D-antigen unit, type 3 32 D-antigen unit). This vaccine will be given at the time period assigned by randomisation. All possible time periods included in the study are within that recommended in the UK as part of routine practice. Participants will have blood sampling prior to vaccination, 14 days following vaccination and at the time of delivery. At delivery a cord blood sample will also be obtained and an infant sample taken from the infants of participating women at 28-42 days after completion of their primary immunisations. There is a paucity of information about functional immunity of anti-PT antibody in serum and colostrum/breastmilk following vaccination in pregnancy. We will be investigating this in two exploratory sub-studies. The first of these (investigation of functional immunity of anti-PT antibody in serum) will be performed on samples being performed as part of the main study. For investigation of functional immunity of anti-PT antibody in colostrum and breastmilk we will ask participants at two participating institutions if they are willing to participate in a breastfeeding sub-study if they decide to breastfeed. For participants who take part in this sub-study a sample of colostrum will be obtained within 48 hours of delivery and a further breast milk sample at 14 days and 5 months following delivery.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 354
Est. completion date May 2021
Est. primary completion date December 10, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 16 Years and older
Eligibility Inclusion Criteria: - Pregnant and not yet having received pertussis vaccination - Willing and able to comply with study procedures and provide informed consent - Documentation of a 20-week anomaly scan with no life limiting congenital anomalies identified Exclusion Criteria: - Age less than 16 years - Confirmed or suspected pertussis in previous five years - Known diagnosis of immune deficiency - Receiving immunosuppressive medication within six months of enrolment in the study (this does not include inhaled or topical steroids) - In the opinion of the investigator is unlikely to complete follow up

Study Design


Intervention

Biological:
Pertussis containing vaccine
Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.

Locations

Country Name City State
United Kingdom St Georges University Hospital NHS Foundation Trust Tooting London

Sponsors (3)

Lead Sponsor Collaborator
St George's, University of London Department of Health, United Kingdom, Thrasher Research Fund

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Functional assays on serum Serum bactericidal assays will be performed. The bactericidal titre is the last serum dilution where =50% killing is observed compared to complement only control. Serum bactericidal assays will be performed and the bactericidal titre will be compared according to the time of vaccination. Samples collected following vaccination, from the cord blood at delivery and in the infants following primary vaccination.
Primary Pertussis specific antibody concentration in cord blood of term infants Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) from cord blood of term infants. This will be measured using ELISA. Delivery of infant
Secondary Pertussis specific antibody concentration in cord blood of preterm infants Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) from cord blood of preterm infants. This will be measured using ELISA. Delivery of infant
Secondary Kinetics of antibody response to pertussis vaccination during pregnancy Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) in maternal blood prior to vaccination, 14 days following vaccination and at delivery. This will be measured using ELISA. Prior to vaccination, 14 days following vaccination, delivery
Secondary Placental transfer of antibody Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) in maternal and cord blood at time of delivery. This will be measured using ELISA. Time of delivery
Secondary Impact of repeated vaccination on antibody response in women who have received a pertussis vaccination in a previous pregnancy Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) in maternal blood prior to vaccination, 14 days following vaccination and at delivery. This will be measured using ELISA. Prior to vaccination, 14 days following vaccination and at delivery
Secondary Antibody concentration in infants following primary immunisation schedule Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) from the infant following primary immunisations. This will be measured using ELISA. 28-42 days following completion of primary immunisations
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A